Patents Assigned to Hudson Institute of Medical Research
-
Patent number: 11590203Abstract: The invention is directed to methods of treating cancers using Interferon-? (IFN-?), wherein the IFN-? includes various natural, synthetic and recombinant IFN-? in compositions.Type: GrantFiled: January 30, 2018Date of Patent: February 28, 2023Assignee: Hudson Institute of Medical ResearchInventors: Paul Hertzog, Zoe Marks, Nollaig Bourke, Sn Sui Lim, Nicole De Weerd, Niamh Mangan, Antony Matthews
-
Publication number: 20220268780Abstract: The present invention relates to methods of predicting endometrial receptivity for embryo implantation in a subject, the method comprising determining a level of podocalyxin in endometrial epithelial cells in the subject. The present invention also relates to methods of monitoring epithelial receptivity and improving epithelial receptivity.Type: ApplicationFiled: June 25, 2020Publication date: August 25, 2022Applicants: HUDSON INSTITUTE OF MEDICAL RESEARCH, MONASH IVF PTY LTDInventors: Guiying Nie, Sophea Heng, Luk Johan Frans Rombauts
-
Publication number: 20220073580Abstract: This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, the amino acid sequence having a mutation or modification for preventing the anti-inflammatory peptide from forming a homodimer.Type: ApplicationFiled: June 30, 2021Publication date: March 10, 2022Applicants: Monash University, Hudson Institute of Medical ResearchInventors: Marcel Nold, Claudia Nold, Andrew Ellisdon, James Whisstock
-
Patent number: 11230583Abstract: The present invention relates to inhibin analogs, their method of production and their use in the treatment and prophylaxis of disease or conditions associated with reduced levels of inhibin and activin-mediated signaling.Type: GrantFiled: November 25, 2016Date of Patent: January 25, 2022Assignee: Hudson Institute of Medical ResearchInventors: Craig Harrison, Kelly Walton
-
Patent number: 11123376Abstract: The present disclosure relates generally to the methods of treatment of mammalian subjects by an enhanced cell-based therapeutic approach in order to facilitate tissue and neuronal repair, regeneration and/or reparation. Medicaments useful in the treatment of mammalian subjects and methods of production of the medicaments are also encompassed by the present disclosure.Type: GrantFiled: June 10, 2016Date of Patent: September 21, 2021Assignees: MONASH UNIVERSITY, HUDSON INSTITUTE OF MEDICAL RESEARCHInventors: Euan Wallace, Rebecca Lim
-
Patent number: 11084855Abstract: This invention relates to polypeptides, including variants of interleukin-37 (IL-37), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric anti-inflammatory polypeptide comprising an amino acid sequence of an IL-37 monomer, the amino acid sequence having a mutation or modification for preventing the anti-inflammatory peptide from forming a homodimer.Type: GrantFiled: June 15, 2016Date of Patent: August 10, 2021Assignees: Monash University, Hudson Institute of Medical ResearchInventors: Marcel Nold, Claudia Nold, Andrew Ellisdon, James Whisstock
-
Patent number: 11046956Abstract: The present disclosure teaches the treatment of a blood pathology, such as a blood pathology associated with impaired hemoglobin synthesis including the treatment of ?-thalassemia or a related hemoglobinopathy.Type: GrantFiled: April 9, 2019Date of Patent: June 29, 2021Assignee: Hudson Institute of Medical ResearchInventor: Jim Vadolas
-
Patent number: 10942189Abstract: The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes. Taught herein is a composition comprising reagents required for the prognostic evaluation. Taught herein are assays comprising determination of levels of the biomarkers IL-8, G-CSF and/or VEGFA in a biological fluid sample taken before embryo implantation.Type: GrantFiled: April 1, 2015Date of Patent: March 9, 2021Assignee: Hudson Institute of Medical ResearchInventors: Lois Salamonsen, Tracey Edgell, Natalie Hannan, Luk Rombauts
-
Publication number: 20190307811Abstract: The present disclosure teaches a method for treating airways disease including ameliorating symptoms of airway inflammation, airway remodeling and airway hyper-responsiveness. The method comprises the administration of an anti-fibrotic agent together with amnion epithelial cells or their functional equivalents or exosomes.Type: ApplicationFiled: August 4, 2017Publication date: October 10, 2019Applicants: HUDSON INSTITUTE OF MEDICAL RESEARCH, HUDSON INSTITUTE OF MEDICAL RESEARCH, MONASH UNIVERSITY, MONASH UNIVERSITYInventors: Chrishan Surendran SAMUEL, Rebecca Seok Wai LIM
-
Publication number: 20180273599Abstract: The present invention relates to inhibin analogs, their method of production and their use in the treatment and prophylaxis of disease or conditions associated with reduced levels of inhibin and activin-mediated signaling.Type: ApplicationFiled: November 25, 2016Publication date: September 27, 2018Applicant: Hudson Institute of Medical ResearchInventors: Craig Harrison, Kelly Walton
